Myocardial infarction with nonobstructive coronary arteries (MINOCA) is common in
clinical practice and accounts for about 10% of all patients presenting with myocardial
infarction (MI) [
[1]
]. The absence of significant coronary stenosis should not be regarded as a benign
feature. Patients with MINOCA are at increased risk of recurrent infarction and mortality
[
[1]
,
[2]
] and should not be dismissed as having a ‘false-positive’ diagnosis of MI. Prompt
recognition of MINOCA is relevant because secondary prevention strategies can improve
patients' prognosis [
[1]
,
[3]
]. However, this entity remains difficult to clinically distinguish from other nonischemic
conditions that manifest with similar symptoms and troponin elevation [
[1]
]. Based on the consensus of international societies, a diagnosis of MINOCA should
be reserved for patients with MI – according to the fourth universal definition –
who also present no stenosis ≥50% in any major epicardial artery on coronary angiography
(Table 1) [
[4]
,
[5]
]. Noteworthy, MINOCA is a working diagnosis and should be confirmed only after carefully
excluding nonischemic etiologies of myocardial injury (i.e., myocarditis), inadvertently
overlooked coronary obstruction (i.e., occlusion of small/distal vessels), and other
possible causes of troponin elevation (i.e., pulmonary embolism). Once these alternatives
have been considered and discarded, a diagnosis of MINOCA can be made [
[4]
,
[5]
]. Early investigation (i.e., within 7–14 days) by cardiac magnetic resonance (CMR)
with late gadolinium enhancement is helpful to assess cardiac anatomy and differentiate
infarct patterns (i.e., subendocardial/transmural) from nonischemic patterns (i.e.,
subepicardial/mid-wall). When CMR reveals a myocardial injury that is consistent with
an ischemic etiology, a systematic search of the potential causes of MINOCA is necessary
to uncover underlying mechanisms [
[1]
]. The presence of plaque rupture/erosion is often reported in MINOCA and can be recognized
by intravascular imaging (i.e., optical coherence tomography [OCT]). Coronary artery
vasospasm may cause persistent ischemia and MINOCA; provocative tests to detect vasomotor
abnormalities are safe and informative when adequately performed, although they are
used rarely in daily practice [
[1]
,
[3]
]. Spontaneous coronary artery dissection represents an uncommon cause of MINOCA,
except in young females [
[1]
]. Coronary microvascular disease is often responsible for MINOCA and could account
for about 20% of all cases [
[1]
]. Identifying the precise mechanisms of MINOCA remains key to assist clinicians in
defining optimal follow-up and treatment strategies in individual patients.
Table 1Contemporary diagnostic criteria for MINOCA.
Society (year) | Diagnostic Criteria for MINOCA |
---|---|
American Heart Association (2019) [
[5]
] |
A diagnosis of MINOCA should be reserved for patients in whom there is an ischemic
basis for their clinical presentation. Thus, in the evaluation of patients with a
suspected AMI (based on cardiac biomarkers and corroborative clinical evidence), despite
the absence of obstructive CAD, it is imperative to exclude:
|
ESC/ACC/AHA/World Heart Federation Task Force (2018) [16] | The diagnosis of MINOCA, like the diagnosis of MI, indicates that there is an ischemic mechanism responsible for the myocyte injury (i.e., nonischemic causes such as myocarditis have been excluded). Furthermore, the diagnosis of MINOCA necessitates that obstructive CAD has not been inadvertently overlooked (i.e., spontaneous coronary artery dissection). |
European Society of Cardiology (2016) [
[4]
] |
The diagnosis of MINOCA is made immediately upon coronary angiography in a patient
presenting with features consistent with AMI, as detailed by the following criteria:
|
ACC/AHA: American College of Cardiology/American Heart Association; AMI: acute myocardial
infarction; CAD: coronary artery disease; ESC: European Society of Cardiology; LBBB:
left bundle branch block; MI: myocardial infarction; MINOCA: myocardial infarction
with nonobstructive coronary arteries; RWMA: regional wall motion abnormalities.
Keywords
Abbreviations:
MINOCA (Myocardial infarction with nonobstructive coronary arteries), MI (Myocardial infarction)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to International Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Myocardial infarction with non-obstructive coronary artery disease.EuroIntervention. 2021; 17: e875-e887https://doi.org/10.4244/EIJ-D-21-00426
- Predictors of mortality in myocardial infarction and nonobstructed coronary arteries: a systematic review and Meta-regression.Am. J. Med. 2020; 133: 73-83.e4https://doi.org/10.1016/j.amjmed.2019.05.048
- Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease.Circulation. 2017; 135: 1481-1489https://doi.org/10.1161/CIRCULATIONAHA.116.026336
- ESC working group position paper on myocardial infarction with non-obstructive coronary arteries.Eur. Heart J. 2017; 38: 143-153https://doi.org/10.1093/eurheartj/ehw149
- Contemporary diagnosis and Management of Patients with Myocardial Infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association.Circulation. 2019; 139: e891-e908https://doi.org/10.1161/CIR.0000000000000670
- Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the START-ANTIPLATELET registry.Int. J. Cardiol. 2021; 345: 7-13https://doi.org/10.1016/j.ijcard.2021.10.138
- Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition.EuroIntervention. 2021; 17: e898-e909https://doi.org/10.4244/EIJ-D-21-00181
- Low-dose Ticagrelor in patients with high ischemic risk and previous myocardial infarction: a multicenter prospective real-world observational study.J. Cardiovasc. Pharmacol. 2020; 76: 173-180https://doi.org/10.1097/FJC.0000000000000856
- P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.BMJ. 2021; 373n1332https://doi.org/10.1136/bmj.n1332
- Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA).Int. J. Cardiol. 2022; S0167-5273 (00249–2)https://doi.org/10.1016/j.ijcard.2022.02.015
Article info
Publication history
Published online: March 09, 2022
Accepted:
March 7,
2022
Received:
March 1,
2022
Identification
Copyright
© 2022 Elsevier B.V. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA)International Journal of CardiologyVol. 354